NOVAPEUTICS
Novapeutics LLC is a biopharmaceutical company spun-out from the University of Pennsylvania that aims to develop a first-in-class, oral curative therapeutic to reverse the course of diabetes by regenerating insulin-producing beta cells. Their approach utilizes small molecule therapeutics to to disrupt menin and mixed lineage leukemia (MLL) proteins, known as a menin inhibitor, which enhancing endogenous beta cell regeneration in diabetes patients. Currently with the support of the SBIR funding from NIH/NIDDK, they have identified promising novel menin inhibitors as their drug leads.
NOVAPEUTICS
Industry:
Biopharma
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.diabetes.novapeutics.com
Total Employee:
1+
Status:
Active
Contact:
(646) 275-9002
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Apache Mobile Non Scaleable Content Google Maps PHP CPanel SSL GoDaddy CDN
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Current Employees Featured
Official Site Inspections
http://www.diabetes.novapeutics.com
Unable to get host informations!!!
More informations about "Novapeutics"
Novapeutics - Crunchbase Company Profile & Funding
Novapeutics LLC is a biopharmaceutical company spun-out from the University of Pennsylvania that aims to develop a first-in-class, oral curative therapeutic to reverse the course of diabetes …See details»
Novapeutics LLC - novel diabetes cure via beta cell regeneration
Mar 2, 2015 · Novapeutics LLC is a biopharmaceutical company spun-out from the University of Pennsylvania that aims to develop a first-in-class, oral curative therapeutic ...See details»
Treating type 2 diabetes with menin inhibitors - Frank Leu
May 1, 2013 · We are developing a novel small molecule T2D therapeutic to enhance endogenous beta cell regeneration in T2D patients by inhibiting menin.See details»
Emerging Disruptive Technologies in the …
Sep 24, 2021 · PharmaFeatures spoke to Frank Leu, CEO of Novapeutics and BioPharMatrix, about the benefits of these disruptive technologies and how companies can implement them successfully. PharmaFeatures: Tell us about …See details»
Diabetes - World Health Organization (WHO)
Clinical Need for Point-of-Care Testing for Diabetes in Clinical and ...
Oct 30, 2024 · Clinical Need for Point-of-Care Testing for Diabetes in Clinical and Laboratory Improvement Amendments–Waived Settings Pamela R. Kushner 0000-0002-5871-1265See details»
The American Diabetes Association Calls for Primary Care Policy …
2 days ago · The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to end diabetes and helping people thrive. For 84 years, the ADA has …See details»
CDH 1 - AdisInsight
Novapeutics is developing CDH 1, a first-in-class, small molecule menin inhibitor for the oral treatment of type 2 diabetes mellitus. CDH 1 blocks the.See details»
Inceptor regulates insulin homeostasis: A new approach for …
2 days ago · Hope for People with Type 2 Diabetes The findings suggest that specifically targeting Inceptor could be a promising strategy for improving the function of insulin-producing cells in …See details»
American Diabetes Association Applauds Landmark …
2 days ago · The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to end diabetes and helping people thrive. For 84 years, the ADA has …See details»
What Kinds of Programs and Services are Available for People
If you have diabetes or are a friend or family member of someone with diabetes, it's important to find places where you can learn about diabetes, be in a supportive environment and have …See details»
9. Pharmacologic Approaches to Glycemic Treatment:
Dec 11, 2023 · Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. 9.1 Treat most adults with type 1 diabetes with continuous …See details»
Issues and Events | Diabetes Care - American Diabetes Association
21 hours ago · The 85th annual American Diabetes Association Scientific Sessions will be held in Chicago, Illinois, 20–23 June 2025, at the McCormick Place Convention Center. Abstract …See details»
Top diabetes associations in Canada: Finding the right …
May 16, 2024 · People living with diabetes can manage their condition, but it can be difficult to do alone. These five organizations aim to change and improve the lives of Canadians living with …See details»
About us - Diabetes Canada
Diabetes Canada is the nation's most trusted provider of diabetes education, research, resources, and services. We've helped millions of Canadians affected by diabetes understand it, manage …See details»
Organization of Diabetes Care
The chronic care model and organization of diabetes care. In many ways, optimal diabetes care delivery reflects the essential components of the CCM . This model aims to transform the care …See details»
A Strategic Plan for Diabetes Canada - Canadian Journal of Diabetes
The Canadian Diabetes Association was established almost 70 years ago and has served as the largest organization in Canada dedicated to improving the lives of individuals diagnosed with …See details»
9. Pharmacologic Approaches to Glycemic Treatment:
Dec 4, 2020 · The American Diabetes Association/European Association for the Study of Diabetes consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 …See details»
Resources - Diabetes Canada
Welcome to our resource centre, which is full of information we have created for people affected by diabetes and those who support them, whether that’s family or healthcare professionals! …See details»
8. Pharmacologic Approaches to Glycemic Treatment:
Nov 24, 2017 · Most people with type 1 diabetes should be treated with multiple daily injections of prandial insulin and basal insulin or continuous subcutaneous insulin infusion. Most individuals …See details»